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ABSTRACT 
Biomaterial science is a very active area of research, which has allowed the successful use of implants in the 
orthopaedic field for over a century. However, implant infection remains a clinical concern as it is associated 
with extensive patient morbidity and a high economic burden, which is predicted to increase due to an ageing 
population. Bacteria are able to adhere, colonise and develop into biofilms on the surface of biomaterials 
making associated infections physiologically different to other post-surgical infections. Unfortunately, biofilms 
exert increased protection from the host immune defence system and an increased resistance to antibiotic 
therapy in comparison to their planktonic counterparts. The aim of this review paper is to assess the current 
knowledge on treatments, pathogenesis and the prevention of infections associated with orthopaedic implants, 
with a focus on total hip arthroplasty.  
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1. Introduction  
Biomaterials have been extensively used as orthopaedic implants for over a century. The early 1900s saw the 
first successful application through use of metallic bone plates for fixation of long bone fractures1. Since then, 
prosthetic implants or catheters for example, have become commonplace in medical practice. Biomaterial 
science has made dramatic improvements in the structural design, functionality and biocompatibility of implants 
however, infection continues to be a significant clinical complication.  
 
When Sir John Charnley developed the low-friction hip arthroplasty in the UK during the early 1960s he was 
aware of the risk of infection and recognised its importance by introducing antibiotics such as gentamycin into 
the bone cement; developed an enclosure that isolated the operating theatre from the rest of the room into which 
filtered air could be passed the so called “Charnley tent” and developed a full-body gown that incorporated an 
exhaust system2. In 1969, John Charnley reported an infection rate of 9.5% following total hip arthroplasty 
(THA)3.  In comparison, contemporary reports of infection in THA vary between 1 to 2%4. This large fall in the 
rate of infection is due to a number of factors: improved patient selection, laminar airflow operating rooms, 
protocols of perioperative antibiotic prophylaxis and an improved generic understanding of the importance of 
sterilisation5. Despite the fall in the rate of infection in the last decades, acquisition of infection is still a clinical 
concern associated with extensive patient morbidity and a high economic burden. Infection has been identified 
as the most common cause of failure of revision THA, which have steadily increased in recent years and are 
forecast to substantially grown over the next decades as the number of primary THA increases due to an ageing 
population6.  
 
Infections associated with orthopaedic implants are physiologically different to other post-surgical infections 
due to the physical presence of the biomaterial itself. Bacterial cells are able to adhere, colonise and develop 
into biofilms on the implant surface. A biofilm consists of a cluster of bacterial cells embedded and surrounded 
within their own extracellular matrix (ECM)7-9. Biofilms protect bacteria from the host immune defence (HID) 
system and also increase bacterial resistance to antibiotic therapy when compared to their planktonic 
counterparts8-10. The aim of this review paper is to assess current knowledge on treatments, pathogenesis and 
prevention of infections associated with implants used in total hip arthroplasty.  
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2. Classification of infection and treatment 
Infection may be classified as early, delayed or late. Early infections, which appear within 3 months of surgery, 
are predominantly a result of perioperative inoculation of highly virulent microorganisms during the surgical 
procedure or following 2 to 4 days prior to complete wound healing. Delayed infections appear between 3 and 
24 months post-surgery. They are also primarily associated with perioperative bacterial inoculation although 
they are generally caused by less virulent microorganisms, thus the longer latency time prior to establishment of 
the infection. Late infections, after 24 months post-surgery, are more commonly associated with contiguous and 
haematogenous acquisition from remote foci of infection. The most frequent foci for late infections are skin, 
respiratory, dental and urinary infections11,12. However, as perioperative antibiotics have been shown to reduce 
the rate of acquisition of late infections, surgical inoculation must contribute in part13.  
 
The long-term use of antibiotics for periprosthetic joint infections (PJI) as a suppressive therapy was advocated 
for approximately 2 decades14. The landmark study by Goulet et al. in 1988 yielded the most successful results 
to date: at a mean of 4 years post-surgical intervention for THA, the prostheses were reported as having 
remained in place with good functionality in 63% of the patients selected for the study15. Patients selected for 
the suppressive therapy were those who refused operative treatment, were unfit for surgical intervention, had 
bacterial infections sensitive to multiple antibiotics, had a deep wound infection within 2 months of the primary 
THA or any combination of these factors15. Suppressive therapy has clear benefits namely low patient morbidity 
and economic burden associated with treatment. However, bacterial evolution is surpassing that of antibiotic 
development and consequently the armoury of antibiotics at the disposal of clinicians is becoming limited 
against increasingly resistant bacterial strains. The emergence of resistant microorganisms, coupled with the 
innate ability of biofilms to evade the HID system, means that antibiotic suppressive therapy alone is no longer 
effective as a suppressive treatment for PJIs16. Therefore, surgical intervention is currently the only definitive 
treatment for PJIs.  
 
Regardless of the chosen surgical intervention, operative debridement and perioperative antibiotic therapy are 
mainstays of treatment protocol. The extent of parenteral antibiotic therapy varies within the literature but 
generally spans between 4 and 6 weeks17-19. A paper by McDonald and colleagues reported on a retrospective 
cohort study of revision patients at the Mayo Clinic compared the reinfection rates of patients receiving less than 
4 weeks of parenteral antibiotic therapy with those receiving equal to or greater than 4 weeks17. 43% patients in 
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the former group compared to only 8% patients in the latter group developed a recurrent infection17. A report by 
Garvin et al. investigated 40 patients who underwent unilateral revision surgery each administered with 6 weeks 
of intravenous antibiotics.  Results showed that only 2 of the 40 hips (5%) developed recurrent infection at an 
average follow-up of 5 years19. Apart from antibiotic therapy and operative debridement, the most appropriate 
surgical intervention must be selected based on strict patient criteria: retention of the prosthesis, re-implantation 
either by a one or two-staged process, permanent resection arthroplasty or amputation (Table 1)20-23. For the 
majority of patients re-implantation is the intervention performed as either a one-stage, direct, or two-stage 
exchange procedure22, which is considered the “gold standard” as it is thought to yield the lowest re-infection 
rates24. 
 
 
 
Table 1: Patient criteria for retention, permanent resection arthroplasty and amputation interventions for total 
hip arthroplasty complicated by infection21-23. 
 
Intervention Patient Criteria 
Retention 1. Well fixed prosthesis without a sinus tract 
2. Infection occurred within 30 days of primary implantation or within 3 weeks 
of onset of infectious symptoms  
3. Absence of excessive scar tissue from previous operative procedures 
4. Culture showing gram-positive organisms that are sensitive to antibiotics 
Permanent resection 
arthroplasty 
1. Non-ambulatory patients 
2. Limited bone stock or poor soft tissue coverage 
3. Infections of highly resistant organisms for which there is no appropriate 
medical therapy 
4. Poor surgical candidate for multiple alternative therapies 
5. Patients that have failed a previous 2-stage exchange in whom the risk of re-
infection after an addition exchange is deemed too high 
Amputation 1. Patients unfit for any alternative treatment in whom emergency elective 
surgery is crucial 
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However, assessment of results identified from the literature revealed one core problem with the current 
treatment: it is based on an abundance of poorly constructed, small sample sized studies, the majority of which 
represent short- or mid-term Level IV evidence (case series). Dramatic variation in case series inclusion criteria, 
such as extent of antibiotic treatment, and underlying patient demographics, make any comparison between 
series futile. No randomised controlled trials have yet been performed comparing the 2 interventions. Two 
systematic published reviews, which compiled the longitudinal studies and case series, each according to 
different inclusion criteria, found no significant difference in reinfection rates, reported at approximately 10%, 
between one- and two-stage procedures25,26. Although eradication of infection does represent an important end-
point, success of treatment must incorporate a balance between overall risk and achieved outcome. A Markov 
expected-utility decision analysis, taking into account factors other than the pure outcome of reinfection rates, 
found the direct exchange procedure to be superior to the two-stage procedure in terms of overall Quality 
Adjusted Life Years delivered to patients27. Nevertheless, there is an urgent need for a well designed, 
multicentre, randomised controlled trial comparing the two interventional treatments.   
 
3. Economic analysis of total hip arthroplasty complicated by infection 
Although several small-scale analyses have contributed to this research area, to date, no formal comprehensive 
economic analysis exists for THA complicated by infection in the UK. According to the National Joint Registry 
620,400 primary THA procedures have been performed between 2003 and 201328. Of the reported cases, 14,903 
(2.4%) implants have been revised, with 2,072 (13.9%) of these revisions accountable to infection. It is 
important to take into account that the reported infection rates are likely under-estimates, as many cases of 
presumed aseptic failure are in fact accountable to misdiagnosed infection29. The revision rate varies depending 
on the type of total hip replacement: a retrospective cohort study Kandala et al. recently analysed 239,000 
patient records from April 2003 to March 2012 held by the National Joint Registry for England and Wales and 
found that 10 year revision rate estimates were highest for uncemented prostheses with ceramic-on-ceramic 
bearing surfaces (3.93-4.33%, depending on the analytical method used) while cemented prostheses with 
ceramic-on-polyethylene bearing surfaces had the lowest revision rates (1.88-2.11% depending on the analytical 
method used)30. 
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The acquisition of a PJI incurs a number of additional costs to health service providers including preoperative 
evaluation, revision procedure, increased length of post-operative stay (LPS), and any required additional 
physiotherapy. It has been estimated that the increase in the LPS for patients receiving treatment for THA 
complicated by infection compared to those receiving a primary THA is 11.5 days, costing £3,34231. When 
extrapolated to all cases of revision in the UK recorded in the National Joint Registry, this adds up to 23,828 
days of hospitalisation and an economic burden of almost £7,000,000.  
 
Klouche and colleagues assessed the economic implication of infected THA in France32. Whilst direct costs are 
not comparable to those in other countries, relative increases in costs between primary THA and revision 
procedures are relevant. The group reported an increased LPS, 24 versus 6 days, and an increased rate of 
transfer to hospital for post-operative care and physiotherapy, 65% versus 55%, for revision versus primary 
THA procedures respectively. The relative increase in total cost of the revision procedure and associated 
treatment was found to be 3.3 times higher than that of a primary THA32.  
 
Ultimately, there is a clear inadequacy of current treatment with regards to the degree of patient morbidity, the 
economic burden it imposes on the National Health System (NHS), the high re-infection rates associated with 
revision procedures and the poor quality evidence that current treatment is based upon. A rapid rise in PJI rates 
is expected in the foreseeable future. This is due to better diagnostic techniques, a growing number of implanted 
prostheses in an aging population and an increased prosthetic residency time33. It is expected that by 2035 23% 
of the total UK population will be over 65, a 6% increase from 201034. In the US, it was estimated that total hip 
replacements would grow by 174% from currently over 300,000 annually to 572,000 by 2030, with total hip 
revision projected to grow by 137%35,36. Similar percentages could be expected for the UK. 
 
While current management of infected THA has been effective, its application is finite, and focus must be put 
on prevention rather than treatment before the expected exponential rise in PJIs surpasses NHS resources and 
becomes an unaffordable economic burden for the UK.  
 
4. Pathogenesis of infections associated with implants 
The space between the biomaterial and the surrounding local tissues, the interstitial milieu, is characterised as a 
locus minus resistentiae, which literally means “place of less resistance”, and is often referred to as an immuno-
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incompetent fibro-inflammatory zone. This phenomenon has been demonstrated by several experimental models 
where the presence of foreign material within a surgical site allows the establishment of infection at 
significantly lower microbial critical doses37. The impaired HID allows for surface colonisation by microbes of 
lower virulence potential, giving rise to an environment for opportunistic infection38. Thus, the higher infection 
rates associated with biomaterials when compared to common surgical site infections is explained by the 
increased susceptibility to infection in the presence of a biomaterial39. In addition to the impaired HID, certain 
biomaterials and/or superficial coatings can physically, chemically and biologically support and enhance 
microbial growth40-44. Coatings and biomaterial surfaces often incorporate superficial pores in order to 
encourage ingrowth of host tissue into the implant thus mediating successful integration45,46. Unfortunately, 
these pores constitute superficial niches that physically protect microbes from phagocytic cells. Bio-resorbable 
biomaterials can locally dissipate nutrients over time that may be used by bacteria to support their own growth 
and proliferation40-43. Moreover, metallic ions released from certain metals, comprised within biomaterials and 
coatings, have been shown to chemically enhance microbial function by altering internal metabolic processes for 
several microbial species44.  The incidence of infection in patients who are immunocompromised  rises.  For 
example patients receiving chemotherapy after removal of a bone tumour show increased levels of infection, 
which may be as high as 11%47.  This may also be associated with the longer operative time and poor soft tissue 
coverage but nevertheless the immunological health of the patient is important. Recent reports on the incidence 
of infection in metal on metal hip replacements suggest that infection may be higher than with more 
conventional hip replacements and this has been attributed to a combination of particulate debris, molecular 
effects of Co and Cr ions on soft tissues, and/or products of corrosion that may change the local environment 
predisposing to infection48,49. 
 
As mentioned earlier, the presence of the biomaterial itself, which provides a surface that serves as anchorage 
for microbes and subsequent biofilm formation, constitutes the problem with regards to establishment of 
infection50. Bacteria involved in biofilm formation show increased protection from the HID system as well as an 
enhanced therapeutic resistance10. Therefore, adherent bacteria in biofilms are significantly harder to eradicate 
through the use of antibiotics in comparison to their planktonic counterparts, thus the need for surgical removal 
of a substantial proportion of infected implants16. 
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4.1 Biofilm formation 
Understanding biofilm development is mandatory for a critical analysis of strategies aimed at eradicating or 
preventing biofilm formation. Distinct stages in the biofilm formation process can be identified (Table 2). 
 
Stage Mechanisms Function 
-Host ECM proteins (i.e. collagen 
fibrinogen, fibronectin, elastin) 
colonise the biomaterial surface. 
-Vroman effect: serum proteins with the 
highest motility arrive first at the 
biomaterial surface and subsequently 
absorb onto it, but are later replaced by 
proteins with less motility and higher 
affinity for the biomaterial surface. 
-Attachment of host cells from local tissue 
and secretion of ECM. 
-Pre-conditioning of the 
biomaterial surface. 
-Attachment of bacteria to the host 
ECM proteins. 
-Expression of adhesins which mediate cell 
anchorage and fixation. 
-Formation of bacterial 
micro-colonies on the 
biomaterial surface. 
-Production of an extracellular 
polymeric biofilm matrix that 
encapsulates the cells. 
-Bacterial cells secrete eDNA, lipids, 
exopolysaccharides and extracellular 
proteins with amyloid (insoluble fibrous 
protein aggregates) properties able to 
polymerise into higher-order structures. 
-Different biofilm components have 
different functions: bacteria-host cells 
interaction, protection, adhesion. 
-Provide protection and a 
means of evading the host 
immune response. 
-The biofilm reaches its critical 
capacity and is disrupted, releasing 
excess bacteria from the matrix that 
either pass to adjacent areas of un-
colonised biomaterial surface or into 
the bulk fluid as planktonic bacterial 
cells. 
-Not understood yet. 
-In staphylococci, Quorum sensing (control 
of gene expression in a cell-density 
dependent manner) and surfactant peptides 
structure biofilms both in vitro and in vivo 
and lead to biofilm detachment. 
-Propagation of infection. 
 
 Table 2: Summary of mechanisms and functions of the different stages involved in biofilm formation51-80. 
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Before biofilm formation, host ECM proteins colonise the biomaterial surface, a phenomenon that is principally 
governed by the Vroman effect, where the highest motility serum proteins arrive first and adsorb onto the 
biomaterial surface, being later replaced by less motile serum proteins with higher affinity for the biomaterial 
surface51,52. In addition to the Vroman effect, host cells from the local tissue attach to the biomaterial surface 
and start depositing an ECM. The host ECM contains proteins such as collagen, fibrinogen, fibronectin or 
elastin, to which bacterial cells adhere through the expression of adhesins, which mediate cell anchorage and 
fixation53. Several of these active adhesive mechanisms are regarded as critical virulence factors and are 
frequently considered for characterisation of clinical isolates in studies of molecular pathogenesis. Bacterial 
strains that do not produce an ECM are comparatively less adhesive. Therefore, they are less likely to cause a 
chronic implant infection54. A study by Davies and Geesey showed that bacterial transcription factors associated 
with ECM production, such as those coding for alginate biosynthesis, are activated and up-regulated in response 
to attachment to a solid surface55. Thus, it can be concluded that is the bacterial attachment itself that initiates 
the subsequent stages in the biofilm formation and maturation process. 
 
Attached bacteria proliferate and form micro-colonies. Initial attachment to the surface of an implant is 
important and can differ between different bacteria. A surface colonised by Staphylococcus aureus  is 
“decorated” with proteins that are covalently anchored to the cell wall peptidoglycan. Structural and functional 
analysis has identified four distinct classes of surface proteins, of which microbial surface component 
recognizing adhesive matrix molecules (MSCRAMMs) are the largest class. These surface proteins have 
numerous functions, including adhesion to and invasion of host cells and tissues, evasion of immune responses 
and biofilm formation. Thus, cell wall-anchored proteins are essential virulence factors for the survival of S. 
aureus in the commensal state56.  Pseudomonas aeruginosa expresses a mucoid exopolysaccharide matrix with 
alginate as a major component, lipopolysaccharide (LPS)57,58 and the filamentous surface appendages flagella 
and pili59,60. Several of these surface-associated structures are known to function as adherence factors or 
adhesins. 
 
The hallmark of biofilm formation is the production of an extracellular polymeric biofilm matrix that 
encapsulates the bacterial cells providing protection and a means of evading the host immune response8,9,61. The 
fact that bacterial cells can secrete extracellular material that helps with attachment was reported by Claude 
Zobell and Esther Allen as early as in 1935: “The film of bacteria may promote the attachment of macroscopic 
11 
 
organisms in different ways. They may form a mucilaginous surface to which the fouling organisms in the 
planktonic or free-swimming stage readily adhere until they can prepare their own holdfast”62. Today we know 
that the extracellular biofilm matrix produced by the majority of microorganisms is not just a slime surrounding 
the cells but a highly ordered structure where protein localization is extensively observed across the matrix as 
well as interactions between components. The biofilm matrix is composed of extracellular DNA (eDNA), lipids, 
exopolysaccharides and extracellular proteins of which many have amyloid-like properties and can polymerize 
into higher–order structures63-65.  
 
The production of the extracellular biofilm matrix establishes the success of biofilm communities by protecting 
the bacterial cells against phagocytosis, antibiotics and high fluid flow conditions66. Several strategies are 
adopted by different microbial species and therefore various compositions are encountered. Some bacteria 
synthesize protein fibres to form a scaffold with structural integrity and rigidity so cells and other matrix 
components like exopolysaccharides can attach to it67-69. The function of some matrix components is to facilitate 
the interaction between bacterial and host cells, such as the curli fibres produced by E. coli cells. Apart from its 
structural function, curli fibres are needed by E. coli cells to attach to various protein components of the host 
cells at the onset of infection70-72. A protective function is seen for other matrix components: the cellulose 
present in E. coli biofilms increases the resistance of the bacterial community to desiccation while the self-
assembling bacterial hydrophobin BslA forms a highly hydrophobic coat over the Bacillus subtilis biofilm 
shielding it from aqueous environments73-75. An adhesive function is seen for the polysaccharide intercellular 
adhesin (PIA) secreted by staphylococci during biofilm maturation76. 
 
Eventually, an established biofilm matrix will reach its critical capacity and get disrupted. At this point excess 
bacteria are released from the biofilm matrix to pass either to adjacent areas of un-colonised biomaterial surface, 
thus propagating the biofilm, or into the bulk fluid as planktonic bacterial cells65,77. Although in recent years 
investigation of biofilm disruptive processes has been intensified, so far we lack understanding of the forces and 
molecular determinants behind the detachment of cells when critical capacity is reached. Understanding these 
mechanisms is of key importance.  
 
It has been shown that bacteria concentrated in a biofilm release small auto-inducer molecules that lead to 
quorum sensing that is able to regulate gene expression. Quorum sensing bacteria produce and release chemical 
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signal molecules that increase in concentration as a function of cell density76. The detection of a minimal 
stimulatory concentration of an auto-inducer above a threshold leads to an alteration in gene expression. Recent 
studies indicate that quorum sensing may play a key role in biofilm structuring and detachment, like the phenol-
soluble modulins, which are surfactant peptides secreted by staphylococci (S. aureus and S. epidermidis are the 
most frequent pathogenic species among orthopaedic clinical isolates of implant associated infections) in a 
quorum-sensing controlled fashion, which have been found to structure biofilms both in vitro and in vivo and 
lead to biofilm detachment76,78,79. However, more research in this exciting area is needed to prevent propagation 
of the biofilm as well as systemic infection. 
 
Finally, it is important to mention that some bacterial species like Pseudomonas aeruginosa display multiple 
phenotypes during development of the biofilm with five stages of biofilm development that includes: (i) 
reversible attachment, (ii) irreversible attachment, (iii) maturation-1, (iv) maturation-2, and (v) dispersion. The 
maturation-1 stage is characterised by layered cells in clusters, with a cluster thickness of less than 10 µm. The 
maturation-2 stage is characterized as a point where there is maximum cell cluster development, with cluster 
thickness up to 100 µm and where the majority of cells are displaced from the substratum. When planktonic 
cells were compared with maturation-2 stage biofilm cells, more than 800 proteins were shown to have a six-
fold or greater change in expression level80.    
 
4.2 Resistive mechanisms of biofilms 
Bacteria within biofilms show higher levels of resistance to antibiotics than their planktonic counterparts81. One 
investigated mechanism is the incomplete penetration of antibiotics through the full depth of the multi-layered 
biofilm matrix, which prevents full eradication of the microbes82-87. Mathematical models have shown that, for 
the majority of antibiotic compounds, no generic barrier to penetration should exist within a biofilm88. However, 
numerous in vitro studies have demonstrated the failure of antibiotics to fully penetrate the biofilm. In 1994 Suci 
and colleagues used attenuated total reflection Fourier transform infrared spectroscopy to monitor transport of 
the fluoroquinolone antibiotic ciprofloxacin to the Pseudomonas aeruginosa biofilm-germanium substratum 
interface, which was significantly impeded by the biofilm82. Earlier in 1992 Hoyle and co-workers demonstrated 
similar results with the antibiotic piperacillin and its diffusion through a dialysis membrane colonised by 
Pseudomonas aeruginosa83. Several studies have shown that polymeric compounds such as the anionic 
polysaccharide alginate exist within the biofilm matrix and that such compounds impede the diffusion of 
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antibiotics through the matrix84-87. A proposed explanation is ionic trapping, whereby the anionic polymeric 
compounds such as alginate attract and stagnate cationic antibiotics such as aminoglycosides. It is also well 
established that the viscoelastic properties of the biofilm, determined by its matrix composition, influence 
antimicrobial penetration89. In contrast to these findings, the successful diffusion of rifampicin and vancomycin 
through a Staphylococcus epidermidis biofilm produced via a comparable method was shown by Dunne and 
colleagues in 1993. However, sterilisation of the biofilm was not accomplished after 72h of antibiotic 
treatment87.  
 
Studies like the ones discussed in the previous paragraph have undoubtedly shown that the biofilm matrix 
retards antibiotic penetration through the biofilm. However, the extent of impedance varies significantly 
between studies and is dependent on both the antibiotic, bacterial type and matrix constituents83,87,90. 
Consequently inadequate penetration cannot fully account for the resistive phenomenon, and it may be 
presumed that other mechanisms are concurrently involved.  
 
Heterogeneity exists within biofilms in three forms: spatial heterogeneity, heterogeneity of response, and 
heterogeneity of cells. Several studies have shown that these concepts of heterogeneity within a biofilm 
constitute an important survival strategy, allowing evasion of antibiotic therapy and persistence of infection91-98. 
Spatial heterogeneity is the distribution of regions of high and low cell growth rate within a biofilm, and was 
identified by Wentland and colleagues in 199691. Depletion of bacterial nutritive compounds or the 
accumulation of inhibitory metabolites within these regions may explain the quiescent or non-growing state of 
the bacterial cells92. Since the mechanism of action of many antimicrobial agents such as penicillin, which 
targets cell wall synthesis, is dependent on bacteria existing in a growing state, these regions of slow-growth 
may explain the inefficiency of many antibiotics to fully eradicate biofilms93. Other studies have also observed 
gradients of physiological activity in response to antibiotic treatment, indicating that the response to antibiotics 
within a biofilm is non-uniform thus contributing to the likelihood of survival of portions of the biofilm. Huang 
et al. grew biofilms of Klebsiella pneumonia and Pseudomonas aeruginosa on stainless steel surfaces in 
continuous-flow annular reactors and treated them with 2mg/ml of the biocide monochloramine for 2h94. Results 
revealed gradients of respiratory activity within biofilms in response to monochloramine treatment: cells near 
the biofilm-bulk fluid interface lost respiratory activity first while greater respiratory activity persisted deep in 
the biofilm. Korber and co-workers also showed that cells located in closest proximity to the biofilm-bulk fluid 
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interface within an established Pseudomonas fluorescens biofilm experienced cell elongation when subjected to 
the fluoroquinolone fleroxacin95. The last phenomenon of heterogeneity refers to the polymicrobial community 
of biofilms. The coexistence of bacterial kingdoms has been shown to provide a competitive advantage, with 
altered sensitivities to antimicrobial agents observed as a result of mutually beneficial relationships established 
within biofilms96-98. Among orthopaedic clinical isolates of implant-associated infections staphylococci (S. 
aureus and S. epidermidis) account for approximately 65% of the pathogenic species found, others being from 
the genus Pseudomonas (8%), Enterococcus (5%), Escherichia (2%) or Sptreptococcus (2%)99. 
 
Several other theories underlying the resistive phenomenon have been put forward, including numerous other 
environmental impacts on antibiotic efficacy100-103, formation of a dormant, protected, spore-like phenotype in 
response to growth on a surface104,105, and amplification of transcription factors coding for antibiotic resistive 
traits106. 
 
Regarding environmental features of biofilms that contribute to the inefficacy of antibiotics, de Beer and 
colleagues demonstrated through the use of miniature electrodes that oxygen can be completely consumed at 
superficial zones of biofilms and therefore, deep zones will consequently contain anaerobic niches100. Several 
antibiotics, including aminoglycosides, have been to shown to be significantly less active and subsequently less 
effective in anaerobic than in aerobic states against the same bacterium102. A study by Zhang et al. demonstrated 
that a difference in local pH>1 between the bulk fluid and biofilm interior as a result of acidic waste product 
accumulation can directly antagonise antibiotic action101. Finally, Prigent-Combaret and co-workers showed that 
bacteria within biofilms encounter higher-osmolarity conditions, greater oxygen limitation, and higher cell 
density than in the liquid phase103. It has been theorised that the stress response due to these environmental 
features may induce a change in the relative concentration of porins in the cell envelope thereby reducing the 
bacterial cells antibiotic permeability and thus the effectiveness of the antibiotic treatment.  
 
A more speculative theory proposes that the resistance observed within biofilms is due to a small subpopulation 
of cells from a dormant, protected, spore-like phenotype in response to growth on a surface, as opposed to 
nutrient limitation104. The fact that planktonic cells that are derived from biofilms are in most cases fully 
susceptible to antibiotics104 seems to support this theory. Moreover, newly formed biofilms are too thin to form 
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physical barriers to antibiotic penetration or metabolite accumulation and consequently the resistance still 
observed must be accountable elsewhere, possibly supporting this alternative hypothesis105.  
 
The final resistive mechanism associated with biofilms is the rapid transfer of genetic transcription factors. 
Generically, gene transfer through plasmid conjugation is an important mechanism of genetic trait transfer. 
However, diverse complex environments such as those observed in biofilms represent an ideal niche for 
augmentation of this phenomenon. Quantitative in situ analysis has shown higher conjugation frequencies for 
sessile bacteria, such as those within biofilms, than their planktonic counterparts106. Microbial biofilms therefore 
epitomise an idyllic environment for amplification of both naturally occurring and induced antibiotic resistive 
traits.   
 
Understanding the various mechanisms discussed in this review paper by which bacteria in biofilms have 
increased resistance to antibiotics, summarised in Table 3, is critical to develop new strategies to prevent biofilm 
formation on the surface of orthopaedic implants.  
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Resistive mechanism Evidence References 
-Incomplete penetration of 
antibiotics through the full 
depth of the multi-layered 
biofilm matrix. 
-Numerous in vitro studies have demonstrated the failure of 
antibiotics to fully penetrate the biofilm. 
-Several studies have shown that polymeric compounds exist 
within the biofilm matrix, i.e. alginate, which impede the 
diffusion of antibiotics through the matrix (perhaps through 
ionic trapping). 
-Viscoelastic properties of the biofilm, determined by its 
matrix composition, influence antimicrobial penetration. 
-82-89 
 
-Heterogeneity: spatial, 
response and cellular. 
-Spatial heterogeneity: regions of high and low cell growth 
rate within a biofilm have been identified. 
-Heterogeneity of response: gradients of physiological activity 
in response to antibiotic treatment identified. 
-Cellular heterogeneity: coexistence of different bacterial 
species provides competitive advantage, with altered 
sensitivities to antimicrobial agents observed as a result of 
mutually beneficial relationships established within biofilms. 
-91-98 
-Environmental features of 
biofilms. 
-Deep zones of the biofilm contain anaerobic niches as oxygen 
can be completely consumed at superficial zones. 
-Difference in local pH>1 between the bulk fluid and biofilm 
interior as a result of acidic waste product accumulation 
demonstrated. 
-Altered internal osmotic environment due to metabolite 
accumulation. 
-100-103 
-Presence of a small sub-
population of cells from a 
dormant, protected, spore-
like phenotype. 
-Planktonic cells derived from biofilms are, in most cases, 
fully susceptible to antibiotics. 
-Newly formed biofilms are too thin to form a physical barrier 
to antibiotic penetration or metabolite accumulation. 
-104,105 
 
-Rapid transfer of genetic 
transcription factors. 
-Diverse complex environments, such as biofilms, augment 
the phenomenon of gene transfer through plasmid 
conjugation. 
-Quantitative in situ analysis has shown higher conjugation 
frequencies for sessile bacteria than for their planktonic 
counterparts. 
-106 
 
  Table 3: Summary of resistive mechanisms of biofilms to antibiotics. 
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5. Preventing biofilm formation: principles and methods 
Due to the multiple mechanisms underlying biofilm resistance discussed in the previous section (4.2) preventing 
or treating PJI is not a simple task. In order to be clinically effective any single method must overcome multiple 
resistive mechanisms. The interstitial milieu represents the forefront of the battle between host and bacterial 
cells99. The aim of prevention is to deter adhesion and subsequent colonisation of the implant surface by 
bacteria, instead allowing osseointegration of host tissue with the implant. This competitive phenomenon is 
known as the ‘race for colonisation’107. Colonisation of the implant surface by local host cells mediates the 
establishment of a tissue seal, preventing bacterial adhesion and subsequent establishment of infection108.  
 
Bactericidal activity of a preventative therapy must reach a therapeutic threshold whereby adjacent bacterial 
cells are eradicated. However, excessive bactericidal activity may have cytotoxic effects on local host tissue 
cells and prevent successful implant-tissue integration. Host tissue-implant integration is imperative to achieve 
implant stability and reduce the risk of aseptic loosening 46. Pin tract infection for external fixation of frames is 
very often associated with relative movement of the pin in the bone and it is believed that this increases bacterial 
colonisation of the implant surface. A required balance is evident: prevention must exert sufficient bactericidal 
toxicity as to prevent implant failure as a result of septic loosening, but not be excessively cytotoxic as to 
prevent osseointegration and aseptic loosening.  
 
Conventional systemic antibiotics administered perioperatively still represent the main prophylactic strategy 
against infection. However, due to the phenomenon of multi-drug resistance associated with biofilms, this 
strategy fails to completely eradicate PJIs109. Additionally, perioperative antibiotics serve no prophylactic 
function against late infection acquired via the haematogenous route109. The majority of new methods are 
designed to complement systemic antibiotic therapy and focus on 1) local delivery of antimicrobial substrates 
from the implant or cavity filling material; 2) preventing the attachment of bacterial onto the implant surface; 
and 3) methods to remove the bacteria from the implant surface making then susceptible to antibiotic therapy in 
their planktonic state. With local delivery, the critical concentration of the bactericidal agent resides directly at 
the implant-soft tissue interface, allowing higher antimicrobial doses to be achieved with lesser risk of systemic 
toxicity and subsequent renal or hepatic complications110.  
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5.1 Internal methods 
Internal methods are those directly associated with the implant surface or bulk material65,111. The use of a 
bioactive bulk material that is intrinsically antimicrobial for implant production would be ideal. Unfortunately, 
few materials that express such antimicrobial properties are sufficiently biocompatible. Additionally, this is 
further complicated by the need for the material to ideally match the mechanical properties of natural bone in 
order to minimise stress shielding or risk of implant fracture. Therefore, modification of the implant surface 
seems the obvious path to follow. Several strategies are under research for implant surface modification: 
alteration of surface nano-topography, generation of an anti-adhesive surface, and superficial surface coatings. 
Although the three strategies will be discussed, in this review we will mainly focus on superficial surface 
coatings due to the abundance of research exploring this strategy. 
 
5.1.1 Alteration of surface nano-topography 
Alteration of surface nano-topography has been shown to affect the degree of bacterial adhesion, with irregular 
surfaces shown to permit a greater level of bacterial adhesion than smooth, regular ones112. In a recent 
comparative study, Koseki et al. evaluated the ability of the main pathogen present in implant-related infections, 
Staphylococcus epidermis, to form biofilms on materials with surfaces with a similar degree of smoothness: 
oxidised zirconium-niobium alloy, cobalt-chromium-molybdenum alloy (Co-Cr-Mo), titanium alloy (TiAl6V4), 
commercially available pure titanium and stainless steel.  After culturing the pathogen on the different surfaces 
for 2-4 h the biofilm coverage rate was similar for all the materials. However, after 6 h the biofilm coverage rate 
for Co-Cr-Mo was significantly lower (p<0.05) than for TiAl6V4, pure titanium and stainless steel. The authors 
concluded that surface properties like the hydrophobicity or low surface free energy of Co-Cr-Mo may influence 
the two-dimensional expansion of Staphylococcus epidermis biofilms on surfaces with similar nano-
topographies113.  
 
The fundamental flaw with nano-topographical manipulation is that bacterial adhesion to smooth surfaces still 
transpires, albeit to a lesser extent than irregular counterparts, and consequently it is unlikely that alteration of 
surface topography alone will prove sufficient as a preventative method. 
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5.1.2 Generation of an anti-adhesive surface 
Conditioning implant surfaces with antifouling agents, creating adhesion resistant surfaces is another proposed 
strategy. Hyaluronic acid, an anionic non-sulfated glycosaminoglycan widely found in connective, epithelial and 
neural ECM, has been shown to greatly reduce bacterial cell surface fractional coverage when coupled with 
biomaterial surfaces both in vitro and in vivo114. Since the underlying mechanism is mediated through water 
molecule interaction, rather than directly with bacterial cells, the same anti-adhesive effects are exerted on local 
host tissue cells. If osseointegration is not achieved then risk of aseptic loosening is increased, limiting the use 
of hydrophilic surfactants and compounds. Other studies have investigated surfaces which have a high 
hydrophobicity. For example diamond-like carbon surfaces doped with nitrogen or silicon show reduced 
Pseudomonas aeruginosa adhesion115.   
 
5.1.3 Superficial surface coatings 
Currently the most successful strategy primarily focuses on superficial surface coatings116. Generally coatings 
are made of either an intrinsically antimicrobial bulk material or a material infused with antimicrobial 
compounds. Chitosan, a natural polysaccharide, is an example of the former. Investigated as a biomaterial due to 
its biocompatibility, biodegradability, bioactivity, osteoconductivity, enhanced wound healing and innate 
antimicrobial properties, chitosan appears ideal for mediating tissue-implant integration and preventing biofilm 
formation117-119. However, studies have demonstrated inadequate bonding strength of chitosan with the implant 
surface120, increasing the risk of coating delamination and thus limiting its use. Nevertheless, the good 
biomaterial properties of chitosan may be exploited using a different approach: Li and colleagues chemically 
functionalised titanium-based bone implants with nano-particle-stabilised chitosan and methotrexate, a synthetic 
compound that interferes with cell growth and is used to treat certain types of cancer and auto-immune 
conditions, for inhibiting both osteoclastoma formation and biofilm formation121. 
 
The majority of antimicrobial compounds investigated for use in orthopaedic coatings have proven bactericidal 
activity, such as common topical disinfectants or systemic antibiotics. Examples of topical disinfectants include 
silver sulfadiazine and chlorhexidine, and especially certain metals such as copper (Cu), zinc (Zn), magnesium 
(Mg) or particularly silver (Ag).  
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A randomised controlled trial compared the efficacy of silver sulfadiazine and chlorhexidine in swine models 
for infection rate reduction122. Bacterial cell adhesion was significantly lower on biomaterials coated with the 
antimicrobial compounds when compared to controls. Additionally, no biofilm formation, or local or systemic 
toxicity, was noted in intervention groups122.  
 
Cu has demonstrated bactericidal properties whilst human cells demonstrate relatively low sensitivities to Cu123. 
Nevertheless, the mechanism of "contact killing" of bacteria by Cu surfaces is still poorly understood. 
Particularly, the influences of bacteria-metal interaction, media composition, and Cu surface chemistry on 
contact killing require further investigation. In a study by Hans and colleagues, copper oxide formation on Cu 
during standard antimicrobial testing was measured in situ using spectroscopic ellipsometry. The authors found 
that CuO significantly inhibited contact killing compared to pure Cu. Conversely, thermally generated Cu2O 
was essentially as effective in contact killing as pure copper. The authors concluded that since it is Cu2O that 
primarily forms on Cu under ambient conditions, antimicrobial objects would retain their antimicrobial 
properties even after oxide (Cu2O) formation124. Cu presents disadvantages though, as studies have shown that 
Cu incorporation within hydroxyapatite coatings does not deter biofilm formation, whilst other metals such as 
silver (Ag) have shown to exert bactericidal activity125. Cu has also been shown to form large fibrous capsules in 
vivo after 28 and 56 days of sub-cutaneous implantation in rats126, which could potentially contribute to an 
increased risk of aseptic loosening. However, Hoene and co-workers carried out a study aimed at evaluating a 
Cu coating produced by galvanic deposition on TiAl6V4 plates in terms of in vivo Cu release and local 
inflammatory reactions for 72 h after intramuscular implantation in rats. Results showed that Cu coated 
TiAl6V4 implants had antibacterial effectiveness in vitro, measurable Cu amounts were released in vivo and 
caused a moderate local inflammatory response127, thus suggesting that fine-tuning of Cu coatings on 
orthopaedic materials could be effective in fighting biofilm formation. 
 
Very recently Grenho and colleagues reported the antibacterial activity and biocompatibility of three-
dimensional and interconnected porous granules of nano-structured hydroxyapatite incorporated with different 
amounts of zinc oxide (ZnO) nano-particles produced using a simple polymer sponge replication method128. The 
composite granules were especially effective at reducing bacterial activity in vitro and in vivo when containing a 
weight percentage of 2% ZnO, with low cell growth inhibition in vitro and no differences in the connective 
tissue growth and inflammatory response after subcutaneous implantation in rats128. These results suggest a 
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promising potential for this composite material for prevention of biofilm formation in vivo. Similarly, the 
antibacterial properties of pure (99.9%) Mg in vitro and in an in vivo rat model of implant-associated 
methicillin-resistant Staphylococcus aureus infection was recently shown129. 
 
The concept of exploiting metals against microorganisms is not novel. In fact, Ag was commonly used in 
ancient history to prevent water contamination. It is the most extensively studied metal for the purpose of 
fighting infection and food preservation. Unlike Cu, the mechanism of action of Ag is well known and it is 
mediated through Ag+ ions, which strongly inhibit growth through suppression of respiratory enzymes, electron 
transport components, and through interference with DNA functions130. The success of silver is well 
documented in applications such as wound dressings, burn creams, sutures and catheters131-136.  
 
Several studies have assessed the antimicrobial efficacy of silver ions (Ag+) and Ag nano-particles against 
biofilm formation and advocate its use in prevention of biofilm-related infections137-141. The antibacterial effect 
of Ag nano-particles has been reported to be both size and shape dependent. However, a study by Actis and 
colleagues aimed at evaluating the effect of three different shapes (spherical, triangular and cuboidal) of Ag 
nano-particles on microbial susceptibility (S. aureus and methicillin-resistant S. aureus) and bone cell viability 
revealed that the shape of Ag nano-particles did not affect microbiota susceptibility or human fetal osteoblasts 
viability141. High concentrations of Ag nano-particles (0.5 nM) granted significant bacterial susceptibility and 
significantly reduced human fetal osteoblasts viability141. In fact, human fetal osteoblasts had increasingly 
reduced viability to lower Ag nano-particle concentrations with an increase in exposure time141. Ag has also 
been used to dope hybrid coatings as reported by Tran and colleagues: hybrid coatings of titanium dioxide and 
polydimethylsiloxane (PDMS) were synthesised to regulate the release of Ag. The coatings, with different 
titanium dioxide:PDMS ratios, were deposited on discs of polyether ether ketone (PEEK) and selected ratios 
were shown to control Ag release and completely inhibit biofilm formation142.   
 
One approach which is currently used in clinical practice is to coat the implant surface with Ag. It has long been 
known that silver is a powerful antibacterial agent: Ag-coated materials have been shown to influence bacterial 
adhesion, and Ag-coated prostheses have been fabricated for clinical testing where they have achieved some 
good results143,144. The antibacterial effects of Ag result from the release of its ions from the implant surface and 
the subsequent thiol bonding to the active site of many metabolic enzymes. Silver has been used in combination 
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with calcium phosphate/hydroxyapatite coatings and ceramics145. Although effective, there is concern that the 
Ag layer may influence the metabolic status of adherent cells as well as the metallurgical properties of the 
implant in vivo. There is also concern that when the Ag release is complete, the implant surface will no longer 
function as a microbicidal agent. However, as most of the infections are associated with the operation then a 
limited release over a matter of weeks is warranted. Although rare, there is also the problem of Ag resistance 
and hypersensitivity to Ag+146. A new approach where Ag is incorporated into the anodised surface of titanium 
has shown to reduce implant related infections by around 50%. In a case-control Wafa et al. showed the overall 
post-operative infection rate of the Ag-coated group of massive implants used to treat bone tumour implants was 
11.8% compared with 22.4% for the control147.    
 
In addition to its proven efficacy against biofilms, Ag overcomes many of the shortcomings of previously 
discussed prevention methods. Silver is non-toxic to human cells at small concentrations whilst highly toxic to 
bacterial cells, allowing the exertion of bactericidal activity with minimal cytotoxic effects148. Furthermore, 
development of microbial resistance against Ag+ is significantly less likely, compared to commonly used 
antibiotics, due to the broad range of mechanisms through which it acts, unlike antibiotics which commonly act 
through a single mode only130. Finally, many of the production methods of silver infusion are cost-effective, i.e. 
immersion in silver nitrate (AgNO3). Regardless, it is the long-term potential to prevent exposure of patients to 
such debilitating revision procedures and the NHS to such economic burden that is the most desirable trait that 
this preventative method has to offer. 
 
Finally, antibiotics infused within coatings have been extensively researched. An approach has been to 
covalently  attach antibiotics such as vancomycin onto the surface of titanium, which has been shown to provide 
a long-lived anti-bacterial layer that should be active over the lifetime of the implant. Once tethered, the 
antibiotic provides a constant level of protection, which might discourage colonization. Because the total 
amount of the agent is small compared to the quantities used for controlled release, it may be less likely to foster 
resistance149. Once formed, these surfaces exhibit antibacterial activity and specificity without development of 
resistance. When implanted into infected femoral medullary canals in rats, it blocks bacterial proliferation and 
osteolysis150. The antimicrobial efficacy of antibiotic infused HA coatings has been demonstrated with multiple 
antibiotics, such as gentamicin, vancomycin, tobramycin and more recently rifampicin151-153. Certain antibiotics 
have been shown to bind poorly to calcium within calcium-phosphate coatings; consequently antibiotic release 
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is too rapid and fails to provide prophylactic protection151. This limits the variety of antibiotics that can be used, 
potentially problematic against multi-resistant strains. Therefore, other antibiotic-infused coatings are being 
investigated, such as lipid-based (purified phosphatidylcholine) materials on titanium and stainless steel154 or 
titania nanotubes loaded inside with poly(lactide-co-glycolide) and chitosan on titanium155. The appropriateness 
of using antibiotics during an era of developing resistance is controversial. Several authors have raised concern 
that prolonged low-level antibiotic release may contribute to selection of antibiotic resistant bacterial strains, 
exacerbating the resistance phenomenon discussed in previous sections. Incorporation of “last resort 
antibiotics”, used to treat severe multi-resistant bacterial strains, has been advised against.  
 
5.2 External methods 
External methods refer to those that are not related directly to the implant. Antibiotic impregnated cement is 
becoming increasingly used, especially in revision cases associated with higher re-infection rates. It has been 
shown to express a biphasic release pattern: an initial high concentration burst release followed by a prolonged, 
sub-therapeutic level of release. Success of antibiotic impregnated cement has been shown156. However, several 
concerns exist with its use. Firstly, conflicting evidence regarding the effect of antibiotic impregnation on 
mechanical properties of cement exists157,158. Secondly, there is concern regarding the sub-therapeutic level of 
antibiotic release and its contribution to the phenomenon of antibiotic resistance. Finally, its use is limited in 
uncemented procedures. An alternative could be using Ag instead of antibiotics. A recently published paper by 
Slane et al. studied the mechanical, material and antimicrobial properties of acrylic bone cement impregnated 
with Ag nano-particles showing that cements modified with Ag nano-particles significantly reduced S. aureus 
and S. epidermis biofilm formation on the surface of the cement while demonstrating mechanical and material 
properties similar to those of the non-impregnated cement159.  
 
For uncemented procedures local delivery of gentamicin from resorbable viscous hydrogels of poly(N-
isopropylacrylamide-co-dimethyl-γ-butyrolactone acrylate-co-Jeffamine® M-1000 acrylamide), which delivered 
the antibiotic with low systemic exposure, has been proposed160. Along this line, polymeric carriers have been 
developed to optimise the release and targeting of antibiotics161. A different approach has been reported by 
Bezuidenhout and co-workers: the release of vancomycin through polyethersulfone membranes from channels 
in cementless TiAl6V4 cubes, thus proposing the novel approach of refillable implants to control biofilm 
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formation162. Of course, one may argue whether this approach should be considered an external or internal 
method, or perhaps a hybrid between the two. 
 
In addition to innovative device technologies, another approach to preventing PJI is through immunization. 
Although a decade ago a universal group B Sreptococcus vaccine was identified by multiple genome screen163, 
an effective vaccine against S. aureus remains elusive, and several clinical trials have failed164.  The limited 
success in these studies may have been the result of not accounting for the temporal variability in antigen 
expression and bacterial growth within a biofilm which may have hidden antigenic sites. However, given the 
remarkable heterogeneity of the single-species and polymicrobial infections evident in an approach that 
concentrates on single antigens, targeting multiple antigens may be required. A vaccine composed of four 
biofilm-upregulated antigens plus antibiotic administration (used to clear planktonic populations) was able to 
prevent biofilm infection where vaccination or antibiotic therapy alone failed. Subsequently, the protective 
efficacy of the S. aureus vaccine has been developed to include gene products with upregulated production in 
biofilms as well as those upregulated in the planktonic mode of growth165. Immunization strategies to prevent 
and treat PJI remains an important area of investigation. 
 
Finally, the transfer of electrical current onto implanted prostheses has also been considered as a minimally 
invasive treatment166. However, this is also in the developing stages. 
 
As a summary, Figure 1 depicts the different strategies discussed in this review to deter biofilm formation on the 
surface of implants.  
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Figure1: Summary of methods discussed in this review to deter formation of biofilms on the surface of 
orthopaedic implants. 
 
  
6. Discussion 
Biomaterial science is a very active and creative area of research which has allowed the successful use of 
biomaterials in the orthopaedic field for over a century. However, infectability of biomaterials remains a clinical 
concern as it is associated with extensive patient morbidity and high economic burden. As discussed in section 2 
of this review paper, the current treatment for THA complicated by infection, operative debridement and 
perioperative antibiotic therapy, is based on a distinct lack of evidence. Consequently, infections associated with 
biomaterials remain a clinically relevant issue. In our economic analysis we calculated an economic burden of 
£7,000,000 for the NHS, forecast to increase due to an ageing population. 
 
As mentioned throughout this review, bacteria are able to adhere, colonise and develop into biofilms on the 
surface of biomaterials making infections associated with biomaterials physiologically different to other post-
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surgical infections. Unfortunately, biofilms express increased protection from the HID system and an increased 
resistance to antibiotic therapy in comparison to their planktonic counterparts8-10. Various resistive mechanisms 
of biofilms to antibiotics (Table 3) have been proposed. Understanding these mechanisms as well as biofilm 
formation and disruption is key to develop new preventive methods to complement classical antibiotic therapy. 
These methods focus on local delivery of antimicrobial compounds from the implant or cavity filling material 
and can be internal, if the implant surface or bulk material are concerned, or external if they are not directly 
related to the implant. Regarding internal methods, several strategies are under investigation, although 
superficial surface coatings are being the focus of extensive research112-155. A variety of antimicrobial 
compounds are used in coatings, from antibiotics to metals, and some studies show encouraging results. Some 
external methods also look promising156-166. However, the use of antibiotics is controversial due to developing 
resistance.  
 
We believe that future research in this area should involve the creativity and diversity of biomaterials science to 
develop “smart” implant surfaces that selectively bind host cells, necessary for implant fixation, while 
discourage bacterial attachment. Perhaps this is not possible by only using implant surface modification and thus 
some external help from injectable biomaterials, i.e. hydrogels or cements, loaded with antimicrobial agents, 
preferably not antibiotics to avoid developing bacterial resistance, is the final piece to the puzzle of preventing 
infections associated with biomaterials. Therefore, research into alternative antimicrobial agents to antibiotics 
should go parallel to the research of new biomaterials as “smart” implants. This will only be possible by 
unravelling and understanding the molecular and cellular mechanisms behind formation and disruption of 
biofilms. 
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